Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries,^[1] especially in relation to approaches making use of new cell therapy or gene therapy developments.^[2] Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.^[3]

In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc.^[3] From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential.^[1] An associated goal was to have more financial flexibility moving forward.^[3] On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY.^[4][3]

The name 'Revvity' itself was formed from a combination of the words "revolution" (abrupt change, in English) and "vita" (life, in Latin).^[1] It was the larger of the two splitees: of around 17,000 employees of the public PerkinElmer, about 11,000 of them were assigned to it, while some 6,000 went to the newly private PerkinElmer.^[4] Initial annual revenues for Revvity were estimated at about $3 billion.^[1] Singh and some other senior executives came to Revvity from PerkinElmer, while others were new hires.^[4] Headquarters for Revvity were kept in the same town as the old PerkinElmer, that being Waltham, Massachusetts.^[1]

Compared with its PerkinElmer past, Revvity was de-emphasizing medical devices in favor of an approach based on reagents and electronic commerce.^[2]